{
    "id": 16463,
    "fullName": "EPHB4 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "EPHB4 over exp indicates an over expression of the EphB4 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2050,
        "geneSymbol": "EPHB4",
        "terms": [
            "EPHB4",
            "CMAVM2",
            "HFASD",
            "HTK",
            "LMPHM7",
            "MYK1",
            "TYRO11"
        ]
    },
    "variant": "over exp",
    "createDate": "01/14/2016",
    "updateDate": "01/14/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7343,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with sEphB4-HSA resulted in decreased tumor growth, and reduced tumor cell proliferation and tumor vessel density and increased apoptosis in xenograft models of EPHB4-over expressing sarcomatoid mesothelioma (PMID: 23721559).",
            "molecularProfile": {
                "id": 16746,
                "profileName": "EPHB4 over exp"
            },
            "therapy": {
                "id": 3013,
                "therapyName": "sEphB4-HSA",
                "synonyms": null
            },
            "indication": {
                "id": 4488,
                "name": "sarcomatoid mesothelioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3429,
                    "pubMedId": 23721559,
                    "title": "EphB4 as a therapeutic target in mesothelioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23721559"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7344,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of sEphB4-HSA and Avastin (bevacizumab) resulted in tumor regression in an EPHB4-over expressing xenograft model of biphasic mesothelioma, and demonstrated improved efficacy over either agent alone (PMID: 23721559).",
            "molecularProfile": {
                "id": 16746,
                "profileName": "EPHB4 over exp"
            },
            "therapy": {
                "id": 4467,
                "therapyName": "Bevacizumab + sEphB4-HSA",
                "synonyms": null
            },
            "indication": {
                "id": 4486,
                "name": "malignant biphasic mesothelioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3429,
                    "pubMedId": 23721559,
                    "title": "EphB4 as a therapeutic target in mesothelioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23721559"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10743,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NVP-BHG712 and Platinol (cisplatin) synergistically inhibited tumor growth and induced apoptosis in cell line xenograft models of melanoma that acquired Platinol (cisplatin) resistance by upregulating Ephb4 expression (PMID: 26390965).",
            "molecularProfile": {
                "id": 16746,
                "profileName": "EPHB4 over exp"
            },
            "therapy": {
                "id": 5604,
                "therapyName": "Cisplatin + NVP-BHG712",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8798,
                    "pubMedId": 26390965,
                    "title": "EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26390965"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 16746,
            "profileName": "EPHB4 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}